Genentech Newswire
Comprehensive Real-Time News Feed for Genentech.
Results 1 - 20 of 581 in Genentech
-
Macrocyclics to Collaborate with Roche on Molecular Innovation for Nuclear Medicine
... worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, ... Comment?
-
Today is Human Genome Day at the US Supreme Court ~pj Updated 4Xs - transcript
... a new and inflexible rule, contrary to normal standing rules and this Court's decision in MedImmune, Inc. v. Genentech, Inc. , 549 U.S. 118 (2007), that petitioners who have been indisputably deterred by Myriad's "active enforcement" of its patent ... Comment?
-
Supreme Court to hear another Case Involving Licensees in Good Standing who Challenge Patent Rights
... shift is appropriate - and in all likelihood will reject the Federal Circuit's decision 9-0. In MedImmune, Inc. v. Genentech, Inc ., 549 U.S. 118, 137 (2007), this Court ruled that a patent licensee that believes that its products do not infringe ... Comment?
-
Blogging from Silicon Valley: Attempting to replicate its success
w/Photo
... successful applicants receiving funding to start a business in Chile for up to six months. Students also visited Genentech Inc., a bio-pharmaceutical company focusing on oncological drugs for the treatment of cancer patients. To reduce any cross ... Comment?
-
BioTech Reports Show Volatile and Profitable Market
San Francisco, CA -- Investing in Biotech has been a difficult sustainable proposition since the start. Comment?
-
Roche, QB3 target life sciences startups in funding plan
Genentech Inc. parent company Roche is throwing in with the University of California's QB3 and Mission Bay Capital to snag seed-stage companies. Comment?
-
Patent Watch: Sanofi-Aventis Deutschland GmbH v. Genentech, Inc.
... and (3) 'whether the impact on comity would be tolerable. On May 10, 2013, in Sanofi-Aventis Deutschland GmbH v. Genentech, Inc. , the U.S. Court of Appeals for the Federal Circuit (Rader, Dyk, Reyna*) affirmed the district court's denial of ... Comment?
-
Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Roche's obinutuzumab significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer Basel, 16 May 2013 -- Roche today announced the first results from CLL11, a phase III study of the investigational ... (more) Comment?
-
Relypsa, Inc. Announces Appointment of as CEO
... leading pharmaceutical and biotechnology companies, including Johnson & Johnson, Affymax, Rhone-Poulenc Rorer and Genentech. Previously, Relypsa has been headed by President and Founder Gerrit Klaerner, Ph.D., who will remain on as a consultant. Mr. ... Comment?
-
Federal Circuit Refuses To Enjoin International Arbitration Of Patent Claims
w/Photo
... other cases , the Federal Circuit reminds us the power is not absolute. In Sanofi-Aventis Deutschland Gmbh v. Genentech, Inc., __ F.3d __, 2013 WL 1921073 (Fed. Cir. May 10, 2013), it affirmed the district court's decision not to enjoin a foreign ... Comment?
-
Genentech Wins New Fda Ok for Lung Cancer Drug, Diagnostic Test
... Sign up for the free GenePool newsletter today! SOUTH SAN FRANCISCO, Calif. & NORTHBROOK, Ill.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of ... Comment?
-
FDA approves Astellas-Genentech lung cancer drug, diagnostic test
A lung cancer drug and diagnostic test from Northbrook-based Astellas Pharma U.S. Inc. and San Francisco-based Genentech Inc. have won regulatory approvals by the U.S. Food and Drug Administration. The companies said Tarceva once-daily tablets has ... Comment?
-
Harvard Law Professor to Direct New Stanford IP Clinic
... legal practice models ranging from appellate work to human rights advocacy. Founded with donations from former Genentech Inc. executive and Stanford Law alum Stephen Juelsgaard, the clinic's focus will be on how intellectual property laws and other ... Comment?
-
Relypsa Announces Appointment of John Orwin as Chief Executive Officer
Mr. Orwin brings over 20 years of diverse experience in the biotechnology and pharmaceutical industries, having held senior positions at leading pharmaceutical and biotechnology companies, including Johnson & Johnson, Affymax, Rhone-Poulenc Rorer and Genentech. Comment?
-
The Myriad Case and 'Gene' Patents: Much Ado about Nothing?
... from the Court could raise. Patent protection has been an important component of the success of companies from Genentech to Myriad and many others, and the prospect of a categorical ban (ironic, in view of the Court's anathema for "bright line" ... Comment?
-
Next IT Welcomes Thomas Morrow, M.D. to Medical Advisory Board
... to ensure improvement in clinical and financial outcomes. Currently, he serves as a Medical Director for Genentech, Inc. Over the course of his career, Dr. Morrow has focused his work on emerging technologies in healthcare, and understanding the ... Comment?
-
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
At the meeting, Genentech medicines will be highlighted in more than 275 abstracts, of which approximately one third were chosen for oral presentations. Comment?
-
FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test ...
SOUTH SAN FRANCISCO, Calif. & NORTHBROOK, Ill. -- -- Genentech, a member of the Roche Group and Astellas Pharma US, Inc. Comment?
-
Medivation, Inc. Names Senior Vice President of New Projects
... president and chief medical officer, oncology at Geron. From 2002 to 2009, Dr. Kelsey held various positions at Genentech, Inc., most recently as vice president, clinical hematology/oncology, where he was responsible for the oncology late stage ... Comment?
-
Research and Markets: Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022
... the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace. Rebif (interferon beta-1a; Merck Serono [EMD Serono ... Comment?
Genentech Forum
Most Popular
- Ogdensburg officer faces harassment charge in Canton - 46 comments
- Obama: There's no longer room for excuses for black men - 91 comments
- Vietnam hands lengthy jail sentences to two patriotic, anti-Chinese activists - 53 comments
- Big victory for immigration reform efforts - 78 comments
- Soldier killed in attack near London barracks, lawmaker says - 137 comments
- Irs Scandal Fallout: Officials Get Senate Grilling On Tea Party Targeting - 99 comments
- Bible Dispute:Atheist's Concern Rejected, Books Returned to Park - 101 comments
- Abuse Of The Law: Bigoted Parents Have Daughter's Girlfriend Arrested - 101 comments
- Holden's signs similar to Mitsubishi - 54 comments
- Syria's rebels blame Putin for prolonged fight - 35 comments
Copyright ©2013 Topix LLC
